Compare ROIV & DRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROIV | DRI |
|---|---|---|
| Founded | 2014 | 1968 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.1B | 25.9B |
| IPO Year | 2021 | 2000 |
| Metric | ROIV | DRI |
|---|---|---|
| Price | $34.40 | $214.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 25 |
| Target Price | $28.94 | ★ $226.50 |
| AVG Volume (30 Days) | ★ 7.1M | 802.2K |
| Earning Date | 05-28-2026 | 03-19-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | N/A | ★ 17.16 |
| EPS | N/A | ★ 10.38 |
| Revenue | $8,260,000.00 | ★ $13,210,900,000.00 |
| Revenue This Year | N/A | $10.58 |
| Revenue Next Year | $744.61 | $3.73 |
| P/E Ratio | ★ N/A | $20.65 |
| Revenue Growth | N/A | ★ 9.39 |
| 52 Week Low | $12.28 | $169.00 |
| 52 Week High | $37.97 | $229.76 |
| Indicator | ROIV | DRI |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 50.05 |
| Support Level | $33.01 | $190.21 |
| Resistance Level | $35.70 | $220.00 |
| Average True Range (ATR) | 1.12 | 5.14 |
| MACD | -0.29 | -1.43 |
| Stochastic Oscillator | 20.61 | 21.37 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Darden Restaurants is the largest global full-service dining operator, with over $12 billion in system sales across 2,159 company-owned stores at the end of fiscal 2025, spanning the US and Canada. The firm operates 10 banners in four segments, including Olive Garden (43% of sales), LongHorn Steakhouse (25%), and fine dining (21%), which includes The Capital Grille, Ruth's Chris, and Eddie V's. The other 11% of sales comes from smaller concepts such as Yard House and Cheddar's. Darden primarily generates revenue through sales of food and beverage items at its company-owned restaurants. It also earns royalties on sales from 154 franchised locations in US and international markets, which sit within the other segment but are immaterial to consolidated results.